{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:04:38Z","timestamp":1767924278225,"version":"3.49.0"},"reference-count":36,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver Cancer"],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; The pandemic of coronavirus disease 2019 (COVID-19) has diverted resources from healthcare services for patients with chronic medical illness such as cancer. COVID-19 also causes organ dysfunction, complicating cancer treatment. In most countries with an outbreak of COVID-19, modifications of cancer management have been adopted to accommodate the crisis and minimize the exposure of cancer patients to the infection. In countries where COVID-19 numbers are subsiding, medical teams should also be prepared to resume normal practices gradually. Here, we aim to review the literature on the impact of COVID-19 on patients with hepatocellular carcinoma (HCC) as well as discuss modifications to the management of HCC during and after recovery from the pandemic. &lt;b&gt;&lt;i&gt;Summary:&lt;\/i&gt;&lt;\/b&gt; Based on current data, 10\u201340% of patients with COVID-19 have hepatic injury characterized by an elevation of transaminases and\/or hyperbilirubinemia. Multiple mechanisms contribute to the hepatic injury, including direct viral entry to hepatocytes\/cholangiocytes, immune-mediated hepatitis, hypoxia, and drug-related hepatotoxicity. In patients with HCC, COVID-19 may exacerbate existing chronic liver disease and complicate the management of cancer. Cancer patients generally have a higher risk of infection and worse outcome, especially those who have recently undergone cancer treatment. Although HCC is under-represented in COVID-19 series, mitigation measures should be implemented to minimize the exposure of patients to the virus. A decision on the treatment of HCC should be balanced with consideration of the availability of medical resources, the level of infection risk of COVID-19, and the risk-benefit ratio of the individual patient. In areas where the COVID-19 outbreak is subsiding, clinicians should be prepared to manage a surge of HCC patients with higher disease burdens and complications. &lt;b&gt;&lt;i&gt;Key Messages:&lt;\/i&gt;&lt;\/b&gt; Mitigation measures to protect at-risk patients, such as those with cancers, from SARS-CoV-2 infection should be exercised and the impact of COVID-19 on this group of patients should be thoroughly studied. <\/jats:p>","DOI":"10.1159\/000510765","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T21:00:34Z","timestamp":1598994034000},"page":"491-502","source":"Crossref","is-referenced-by-count":52,"title":["Impacts of COVID-19 on Liver Cancers: During and after the Pandemic"],"prefix":"10.1159","volume":"9","author":[{"given":"Stephen\u00a0Lam","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-3474","authenticated-orcid":false,"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2021225"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30558-4"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15047"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.03.031"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0360-5"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(10)60507-5"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2015.09.007"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S41206"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30086-4"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa247"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14435"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30057-1"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.40176"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.060"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.00197.x"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30076-X"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30150-9"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.007"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3029-z"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz156.008"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.005"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt247"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081084"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy408"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.016"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.005"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.002"}],"container-title":["Liver Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/510765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/510765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:59:31Z","timestamp":1745423971000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000510765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,9,22]]},"published-print":{"date-parts":[[2020,9,29]]}},"URL":"https:\/\/doi.org\/10.1159\/000510765","archive":["Portico"],"relation":{},"ISSN":["2235-1795","1664-5553"],"issn-type":[{"value":"2235-1795","type":"print"},{"value":"1664-5553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}